Bausch + Lomb reports 24-month U.S. ELIOS glaucoma trial results with 76% achieving ≥20% IOP reduction

Reuters03-23

Bausch + Lomb reports 24-month U.S. ELIOS glaucoma trial results with 76% achieving ≥20% IOP reduction

Bausch + Lomb reported positive 24-month results from a pivotal U.S. clinical trial of the ELIOS System, an implant-free excimer laser procedure intended to reduce elevated intraocular pressure in open-angle glaucoma.
The prospective, multicenter study enrolled 318 patients at 20 U.S. sites who had mild to moderate primary open-angle glaucoma and cataracts.
Unmedicated diurnal intraocular pressure was reduced by at least 20% in 76% of patients, and the average decrease was 7.4 mmHg.
At 23 months, 82% of patients were medication-free, and no intraoperative complications were reported.
Topline results were scheduled to be discussed during a company R&D webinar, and detailed results were slated for submission to a future medical meeting and a peer-reviewed journal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch + Lomb Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260323739970) on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621777402?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621777402","market":"us","top_or_hot":-1,"title":"Bausch + Lomb reports 24-month U.S. ELIOS glaucoma trial results with 76% achieving ≥20% IOP reduction","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bausch + Lomb reports 24-month U.S. ELIOS glaucoma trial results with 76% achieving ≥20% IOP reduction\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Bausch + Lomb reported positive 24-month results from a pivotal U.S. clinical trial of the ELIOS System, an implant-free excimer laser procedure intended to reduce elevated intraocular pressure in open-angle glaucoma.\n        </li>\n<li>\n          The prospective, multicenter study enrolled 318 patients at 20 U.S. sites who had mild to moderate primary open-angle glaucoma and cataracts.\n        </li>\n<li>\n          Unmedicated diurnal intraocular pressure was reduced by at least 20% in 76% of patients, and the average decrease was 7.4 mmHg.\n        </li>\n<li>\n          At 23 months, 82% of patients were medication-free, and no intraoperative complications were reported.\n        </li>\n<li>\n          Topline results were scheduled to be discussed during a company R&amp;D webinar, and detailed results were slated for submission to a future medical meeting and a peer-reviewed journal.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch + Lomb Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260323739970) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bausch + Lomb reports 24-month U.S. ELIOS glaucoma trial results with 76% achieving ≥20% IOP reduction</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBausch + Lomb reports 24-month U.S. ELIOS glaucoma trial results with 76% achieving ≥20% IOP reduction\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-23 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bausch + Lomb reports 24-month U.S. ELIOS glaucoma trial results with 76% achieving ≥20% IOP reduction\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Bausch + Lomb reported positive 24-month results from a pivotal U.S. clinical trial of the ELIOS System, an implant-free excimer laser procedure intended to reduce elevated intraocular pressure in open-angle glaucoma.\n        </li>\n<li>\n          The prospective, multicenter study enrolled 318 patients at 20 U.S. sites who had mild to moderate primary open-angle glaucoma and cataracts.\n        </li>\n<li>\n          Unmedicated diurnal intraocular pressure was reduced by at least 20% in 76% of patients, and the average decrease was 7.4 mmHg.\n        </li>\n<li>\n          At 23 months, 82% of patients were medication-free, and no intraoperative complications were reported.\n        </li>\n<li>\n          Topline results were scheduled to be discussed during a company R&amp;D webinar, and detailed results were slated for submission to a future medical meeting and a peer-reviewed journal.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch + Lomb Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260323739970) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BLCO","symbol_name":"博士伦","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL8ykCYg:1","article_id":"2621777402","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621777402","pubTimestamp":1774263702,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Bausch + Lomb reported positive 24-month results from a pivotal U.S. clinical trial of the ELIOS System, an implant-free excimer laser procedure intended to reduce elevated intraocular pressure in open-angle glaucoma.The prospective, multicenter study enrolled 318 patients at 20 U.S. sites who had mild to moderate primary open-angle glaucoma and cataracts.Unmedicated diurnal intraocular pressure was reduced by at least 20% in 76% of patients, and the average decrease was 7.4 mmHg.At 23 months, 82% of patients were medication-free, and no intraoperative complications were reported.Topline results were scheduled to be discussed during a company R&D webinar, and detailed results were slated for submission to a future medical meeting and a peer-reviewed journal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only an","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BLCO":"博士伦","BK4198":"医疗保健用品"},"translate_title":"博士伦报告24个月美国ELIOS青光眼试验结果76%实现IOP降低≥20%","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLCO":0.9},"content_text":"Bausch + Lomb reports 24-month U.S. ELIOS glaucoma trial results with 76% achieving ≥20% IOP reduction\n    \n\n\n          Bausch + Lomb reported positive 24-month results from a pivotal U.S. clinical trial of the ELIOS System, an implant-free excimer laser procedure intended to reduce elevated intraocular pressure in open-angle glaucoma.\n        \n\n          The prospective, multicenter study enrolled 318 patients at 20 U.S. sites who had mild to moderate primary open-angle glaucoma and cataracts.\n        \n\n          Unmedicated diurnal intraocular pressure was reduced by at least 20% in 76% of patients, and the average decrease was 7.4 mmHg.\n        \n\n          At 23 months, 82% of patients were medication-free, and no intraoperative complications were reported.\n        \n\n          Topline results were scheduled to be discussed during a company R&D webinar, and detailed results were slated for submission to a future medical meeting and a peer-reviewed journal.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch + Lomb Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260323739970) on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621777402","isCrawlerRequest":true}